论文部分内容阅读
目的:探讨阿司匹林对2型糖尿病患者血小板膜糖蛋白CD62P表达水平的影响。方法:采用流式细胞术测定42例2型糖尿病伴微血管病变组血小板CD62P的表达,并与36例不伴微血管病变组和30例正常对照组比较,观察阿司匹林治疗前后CD62P的变化。结果:糖尿病伴微血管病变组CD62P(12.1±4.9)%与不伴微血管病变组(7.4±3.2)%,均较正常组(3.2±1.2)%显著性增高(P<0.01),经以阿司匹林为基础的抗血小板治疗后糖尿病伴微血管病变组CD62P(11.1±4.2)%,无明显改变(P>0.05),不伴微血管病变组CD62P(5.7±2.8)%,显著性降低(P<0.05)。结论:2型糖尿病患者尤其合并微血管病变者CD62P明显增高,阿司匹林能够显著降低2型糖尿病不伴微血管病变者血小板CD62P的表达水平,但对已有微血管病变组作用不明显。
Objective: To investigate the effect of aspirin on platelet glycoprotein CD62P expression in type 2 diabetic patients. Methods: The expression of CD62P on platelet in 42 patients with type 2 diabetes mellitus and microangiopathy was measured by flow cytometry. The changes of CD62P before and after aspirin treatment were compared with those of 36 patients without microangiopathy and 30 normal controls. Results: Compared with the normal group (3.2 ± 1.2)%, the CD62P (12.1 ± 4.9)% and the non-MCA group (7.4 ± 3.2)% in diabetic patients with microvascular disease were significantly increased (P <0.01) There was no significant difference in CD62P (11.1 ± 4.2)% of the patients with diabetes mellitus and microangiopathy after antiplatelet therapy. The CD62P (5.7 ± 2.8)% of the patients without diabetes mellitus were significantly decreased (P <0.05). Conclusion: CD62P in patients with type 2 diabetes mellitus, especially those with microvascular disease, is significantly higher. Aspirin can significantly reduce the expression of CD62P on platelet in patients with type 2 diabetes mellitus without macroangiopathy, but not in patients with preexisting microvascular disease.